
TPT-004, a TPH-1 inhibitor, significantly reduced vascular remodeling and improved right heart function in SuHx-induced PAH in rats. The inhalation route limited systemic exposure, highlighting a safer delivery method. RNA sequencing revealed downregulation of circFoxp1 and immune-modulating pathways. Despite limitations in model scope and sex bias, the study supports TPT-004 as a novel therapeutic candidate for future clinical trials.
Like
Save
Share